Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers
Phase of Trial: Phase II
Latest Information Update: 27 May 2016
At a glance
- Drugs Bevacizumab (Primary) ; Pertuzumab (Primary) ; Octreotide
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 11 Sep 2014 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.